What is OSM Series 4?
The Triazolopyrazine (TP) Series, or Series 4, is the latest of the OSM series. It was announced by MMV and on the OSM blog via the briefing document and as a general description on September 10th 2013.
The series arises from work performed at Pfizer (that cannot be fully disclosed) which was followed by some hit-to-lead work funded directly by MMV and performed by a CRO (which can). The series includes many potent compounds, some with promising physicochemical properties, that are non-toxic and which clear assays such as hERG. Most importantly, members of the series have proven to be potent in vivo.